Although favorable demographics and the launch of innovative new products will drive continued growth in the US market for skin replacements and substitutes, challenges in the biologic product segment, including reimbursement issues and increased regulatory oversight, will hinder market expansion to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for skin replacements and substitutes in the US across a 10-year period.


Amniotic-derived allografts have experienced rapid adoption in the biologic skin replacement and substitute segment.

Which companies have benefited most from the adoption of these products?

How has this shift in product preference affected the traditional allograft market? 

Will the trend toward increased use of amniotic products continue?

How will increased regulatory oversight of amniotic tissue products affect existing amniotic allografts and the development of new products?

Reimbursement changes in the US have affected payment for skin replacements and substitutes.

What is the current reimbursement system for skin replacements and substitutes?

What are some strategies companies can employ to receive favorable reimbursement?

Product launches, acquisitions, and partnerships represent key competitive strategies in this space.

Which competitors are launching new products and in which segments? 

Which segments will see the most acquisition activity?

How are partnerships and acquisitions helping smaller companies compete with more established competitors?

Clinical data are of utmost importance to physicians when choosing skin replacements and substitutes. 

Why do physicians feel so strongly about clinical data when it comes to skin replacements and substitutes?

Which companies are investing in clinical trials? 

How have results from recent clinical trials affected company performance? 

Table of contents

  • United States
    • Abstract
    • Executive Summary
      • COVID-19 Updates
      • Market Highlights
      • Competitive Highlights
      • Market Developments
      • End-User Insights
      • Procedures Covered
      • Products Covered
    • Key Report Updates
    • COVID-19 Analysis
      • Market Impact
      • Guidance and Recommendations
      • Industry and Clinician Perspectives
      • Major Market Forecast Changes and Assumptions
      • Competitive Impact
    • Skin Replacement and Substitute Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
        • Reimbursement
        • Clinical Data
        • Product Improvements and Innovations
        • Mergers, Acquisitions, and Partnerships
        • Distribution and Sales Network
        • Physician Training and Marketing
        • Sites of Service
      • Market Developments
    • Biologic Skin Replacement and Substitute Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • By Material
        • By Product Type
        • By Product Feature
        • By Storage Type
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
    • Biosynthetic Skin Replacement and Substitute Market
      • Market Highlights
      • Market Definitions
      • Market Forecast Data
        • By Product Type
        • By Storage Type
      • Competitive Highlights
      • Market Shares
      • Competitive Factors and Strategies
    • Appendix
      • Abbreviations
      • Bibliography

Author(s): Mark O'Reilly, MSc

Mark O'Reilly is an analyst on the Orthopedics, Dental, and Aesthetics Medtech Insights team at DRG (Part of Clarivate), focused on the skin replacement and substitute, spinal implant, and large-joint reconstructive implant markets. Mark holds both a Bachelor’s and Master’s degree in Biomedical Engineering from the University of Guelph and Western University, ;